<DOC>
	<DOCNO>NCT01802645</DOCNO>
	<brief_summary>The aim study investigate follow schedule efficacy regard response rate neoadjuvant treatment patient non-resectable liver metastasis : - Cetuximab/FOLFOXIRI cetuximab/FOLFIRI patient ras wild type tumour - Bevacizumab/FOLFOXIRI FOLFOXIRI patient ras mutant tumour .</brief_summary>
	<brief_title>Cetuximab/FOLFIRI With Without Oxaliplatin FOLFOXIRI With Without Bevacizumab Neoadjuvant Treatment Non-resectable Colorectal Liver Metastases</brief_title>
	<detailed_description>Patients liver metastasis colorectal without know extrahepatic metastasis screen study include ra status ( b-raf status accord local standard ) . Patients receive chemotherapy accord allocation re-evaluated resectability every 8 week maximum 6 month . Resectable patient resect receive adjuvant treatment complete 12 cycle . In certain circumstance , second resection allow within study . Patients randomize use web-based computer system allow randomization key basic characteristic enter . Patients ras wild-type tumour randomize receive : - Cetuximab/FOLFIRI - Cetuximab/FOLFOXIRI Patients ras mutation randomize receive : - FOLFOXIRI - FOLFOXIRI/bevacizumab Chemotherapy dose adjust risk toxicity treatment arm . Stratification perform accord : - Number metastasis ( &lt; 5 vs. ≥ 5 metastasis ) - Primary tumour situ - Centre Treatment regimens For dose reduction condition continue please refer full protocol . All drug use within label approve dos . B-raf mutation determine accord local standard . If b-raf mutation know randomization , investigator consider patient ra wildtype OR ra mutant patient . Cetuximab/FOLFIRI : Cetuximab 400 mg/m² ( first dose , 2 h ) , 250 mg/m² ( 1 h ) weekly Irinotecan 180 mg/m² , d-l Folinic acid 400 mg/m² ( 2 h ) , 5-FU 400 mg/m² ( Bolus ) , 5-FU 2400 mg/m² ( 46 h ) every 2 week Cetuximab/FOLFOXIRI : Cetuximab 400 mg/m² ( first dose , 2 h ) , 250 mg/m² ( 1 h ) weekly Irinotecan 125 mg/m² , Oxaliplatin 85 mg/m² ( 2 h ) , d-l Folinic acid 400 mg/m² ( 2 h ) , 5-FU 3200 mg/m² ( 46 h ) every 2 week FOLFOXIRI : Irinotecan 165 mg/m² , Oxaliplatin 85 mg/m² ( 2 h ) , d-l Folinic acid 400 mg/m² ( 2 h ) , 5-FU 3200 mg/m² ( 46 h ) every 2 week Bevacizumab/FOLFOXIRI : Bevacizumab 5 mg/kg ( 90 - 30 min i.v . ) , Irinotecan 165 mg/m² , Oxaliplatin 85 mg/m² ( 2 h ) , d-l Folinic acid 400 mg/m² ( 2 h ) , 5-FU 3200 mg/m² ( 46 h ) every 2 week Evaluation response resection Patients evaluate response imaging technique baseline every 8 week . The finding discuss resectability within two week tumour assessment local multidisciplinary team . Technically resectable patient offer liver resection . The treatment continue liver resection maximum six month ( 12 cycle ) . Adjuvant treatment After liver resection , adjuvant treatment recommend schedule preoperatively , maximum combine pre- postoperative treatment 12 cycle . If less three postoperative cycle remain , postoperative treatment start ( see chapter 9.10 ) . Follow After resection , patient follow 5 year randomization . This include - image clinical investigation every three month first 2 year , every six month ( patient without tumour progression / recurrence ) - survival status surgical/medical treatment every three month first 2 year every six month ( patient )</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patients enrol , condition apply : 1 . Nonresectable , histologically confirm , synchronous metachronous colorectal liver metastasis . 2 . Nonresectability document local multidisciplinary tumour board participation surgeon experience liver surgery . Patients enrol ) technically nonresectable ( locally determine multidisciplinary team discussion base remain functional liver tissue resection , i.e . ) involvement portal vein , hepatic vein , portal vein liver lobe hepatic vein drain segment liver lobe , ii ) reason less 30 % remain functional liver tissue resection ) / b ) ≥ 5 liver metastasis / c ) regard nonresectable reason ( description necessary ) 3 . Patients simultaneous liver metastasis eligible , 1. primary tumour resect least 1 month prior chemotherapy 2. follow condition apply : ) primary tumour clearly resectable , ii ) radiation therapy plan , iii ) liver resection plan resection primary operation resection primary , iv ) twostage liver resection plan , v ) effort make exclude additional distant metastasis . 4. WHO PS ≤ 1 5 . Written inform consent 6 . Adequate bone marrow function , liver function ( neutrophils &gt; 1.5 x 109/l ; platelet &gt; 100 x 109/l ; haemoglobin &gt; 5.0 mmol/l ( 8.0 g/dl ) ; bilirubin ≤ ULN ≤ 1.5 x ULN increase 25 % within last 4 week ; SGOT SGPT &lt; 5 x UNL ) 7 . Age ≥ 18 year 1 . Any evidence extrahepatic metastasis , distant lymph node metastasis primary tumour recurrence 2 . ( delete ) 3 . Prior systemic antitumour therapy anti EGFR , antiangiogenetic drug chemotherapy ( except adjuvant chemotherapy interval ≥ 6 month combination radiation radio sensitizer ) 4 . Radiotherapy major abdominal thoracic surgery ( exclude diagnostic intervention venous port implantation ) ≤ 4 week study entry 5 . Renal insufficiency serum creatinine ≥ 1.5 x UNL . If serum creatinine 1.0 1.5 x UNL , creatinine clearance accord CockroftGault formula ≥ 60 ml/min 6 . Hypertension arterial blood pressure &gt; 150/90 mmHg 7 . Severe uncontrolled cardiovascular disease ( congestive heart failure NYHA III IV , unstable angina pectoris , history myocardial infarction within last 12 month , significant arrhythmia ) 8 . Known proteinuria &gt; 1 g/day ( test proteinuria 1+ urinary dipstick analysis ) 9 . Peripheral neuropathy &gt; CTC grade I 10 . Concurrent systemic immune therapy , chemotherapy , hormone therapy , patient receive immune suppressive treatment ( i.e . transplantation , severe rheumatologic disease ) 11 . Participation clinical trial investigational agent within 30 day start treatment study 12 . Active treatment 1. peptic ulcer bleed erosive esophagitis / gastritis within 3 month study 2. pulmonary embolism , severe unstable angina pectoris myocardial infarction , stroke transient ischemic attack within 12 month study 3. deep vein thrombosis within 4 week study 13 . Inflammatory bowel disease 14 . History malignancy , patient 5 year disease free , exception colorectal cancer , adequately treat basal cell squamous cell carcinoma skin insitu cervical cancer within 5 year study 15 . History brain metastases 16 . History severe psychiatric illness 17 . Active drug alcohol abuse 18 . Known hepatitis B C HIV infection 19 . Breast feed pregnant woman 20 . Lack effective contraception ( male female patient ) 21 . Known intolerance one follow drug : cetuximab , bevacizumab , oxaliplatin , irinotecan , 5FU , folinic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>neoadjuvant</keyword>
	<keyword>cetuximab</keyword>
	<keyword>irinotecan</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>5-FU</keyword>
	<keyword>Resection</keyword>
	<keyword>colorectal liver metastasis</keyword>
	<keyword>liver resection</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>k-ras</keyword>
	<keyword>non-resectable</keyword>
</DOC>